Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$98.98 - $115.74 $21.1 Million - $24.7 Million
213,350 Added 55.06%
600,815 $69.5 Million
Q2 2023

Aug 14, 2023

BUY
$96.34 - $112.38 $8.97 Million - $10.5 Million
93,064 Added 31.61%
387,465 $39.9 Million
Q1 2023

May 15, 2023

BUY
$107.32 - $113.5 $1.08 Million - $1.14 Million
10,052 Added 3.54%
294,401 $32.1 Million
Q4 2022

Feb 14, 2023

BUY
$62.39 - $113.8 $482,524 - $880,129
7,734 Added 2.8%
284,349 $32.4 Million
Q3 2022

Nov 14, 2022

BUY
$58.92 - $84.67 $7.37 Million - $10.6 Million
125,012 Added 82.46%
276,615 $18.5 Million
Q2 2022

Aug 15, 2022

SELL
$79.4 - $116.36 $994,961 - $1.46 Million
-12,531 Reduced 7.63%
151,603 $12 Million
Q1 2022

May 16, 2022

SELL
$86.42 - $109.81 $939,471 - $1.19 Million
-10,871 Reduced 6.21%
164,134 $18.4 Million
Q4 2021

Feb 14, 2022

SELL
$98.56 - $119.91 $1.63 Million - $1.99 Million
-16,573 Reduced 8.65%
175,005 $15.8 Million
Q3 2021

Nov 15, 2021

SELL
$91.91 - $110.37 $2.36 Million - $2.83 Million
-25,667 Reduced 11.81%
191,578 $21 Million
Q2 2021

Aug 16, 2021

BUY
$86.24 - $95.92 $18.7 Million - $20.8 Million
217,245 New
217,245 $20.3 Million

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.